格隆汇10月14日丨大洋生物(003017.SZ)公布，预计前三季度归属于上市公司股东的净利润7,400万元— 9,000万元，比上年同期增长44.35%—75.56%，扣除非经常性损益后的净利润6,700万元—8,200万元，比 上年同期增长39.04%—70.17%。 本报告期内，归属于上市公司股东的净利润较上年同期上升44.35%-75.56%，主要是受市场影响，推动 了主产品碳酸钾和兽用原料药的需求，与上年同期相比销量与价格均有所上涨，毛利率上升所致。 ...

报告期内，归属于上市公司股东的净利润较上年同期上升44.35%-75.56%，主要是受市场影响，推动了 主产品碳酸钾和兽用原料药的需求，与上年同期相比销量与价格均有所上涨，毛利率上升所致。 智通财经APP讯，大洋生物(003017.SZ)披露2025年前三季度业绩预告，公司预计归属于上市公司股东的 净利润7400万元至9000万元，同比增长44.35% 至75.56%;扣除非经常性损益后的净利润6700万元至8200 万元，同比增长39.04%至70.17%。 ...

Core Viewpoint - The company, Dayang Bio (003017.SZ), anticipates a significant increase in net profit for the first three quarters of 2025, driven by rising demand for its main products, potassium carbonate and veterinary raw materials [1] Financial Performance - The company expects net profit attributable to shareholders to be between 74 million and 90 million yuan, representing a year-on-year growth of 44.35% to 75.56% [1] - The net profit after deducting non-recurring gains and losses is projected to be between 67 million and 82 million yuan, indicating a year-on-year increase of 39.04% to 70.17% [1] Market Factors - The increase in net profit is primarily attributed to market influences that have boosted the demand for the company's main products [1] - Both sales volume and prices of potassium carbonate and veterinary raw materials have risen compared to the same period last year, contributing to the improved gross margin [1]

本报告期内，归属于上市公司股东的净利润较上年同期上升44.35%-75.56%，主要是受市场影响，推动 了主产品碳酸钾和兽用原料药的需求，与上年同期相比销量与价格均有所上涨，毛利率上升所致。 格隆汇10月14日丨大洋生物(003017.SZ)公布，预计前三季度归属于上市公司股东的净利润7,400万元— 9,000万元，比上年同期增长44.35%—75.56%，扣除非经常性损益后的净利润6,700万元—8,200万元，比 上年同期增长39.04%—70.17%。 ...

大洋生物10月14日公告，预计前三季度归母净利润7400万元-9000万元，同比增长44.35%-75.56%。业绩 预增主要是受市场影响，推动了主产品碳酸钾和兽用原料药的需求，与上年同期相比销量与价格均有所 上涨，毛利率上升所致。 ...

大洋生物公告，预计2025年前三季度净利润为7400万元，比上年同期的5126.58万元增长 44.35%-75.56%。报告期内，主产品碳酸钾和兽用原料药需求增加，销量与价格上涨，毛利率上升。 ...

Group 1: Potassium Carbonate and Bicarbonate Industry - Potassium carbonate is a key raw material in various industries including chemicals, pharmaceuticals, pesticides, light industry, and food [1] - The company is a leading player in the potassium carbonate and bicarbonate industry, recognized as a national high-tech enterprise and a "little giant" enterprise [1] - The production of potassium bicarbonate is increasingly utilized in food as an acidity regulator and chemical leavening agent, with growing consumption driven by health awareness [1] Group 2: Amprolium Hydrochloride Application - Amprolium hydrochloride is primarily used in poultry, cattle, and sheep, with increasing demand due to rising per capita consumption of poultry meat and the solidification of large-scale farming practices [2] - The company's clean production project for amprolium hydrochloride has been recognized as a "National Torch Program Industrialization Demonstration Project" [2] - The production process incorporates resin adsorption and distillation to address wastewater treatment challenges, showcasing significant environmental advantages [2] Group 3: Fluorochemical Industry Potential - The fluorochemical sector, including fluorinated intermediates, pharmaceuticals, pesticides, dyes, and surfactants, has substantial development potential [3] - The company has over 30 years of experience in fluorochemical production, being a major supplier of 2-chloro-6-fluoro series products in both domestic and international markets [3] - The company possesses pilot technology for PEEK intermediates, which have excellent comprehensive performance [3]

Core Insights - The company achieved double-digit growth in both revenue and net profit during the first half of 2025, despite a challenging global economic environment and fluctuations in raw material prices [1][2] - The "one body, two wings" industrial structure has proven effective, with significant contributions from various business segments [2][3] Financial Performance - The company reported a revenue of 499 million yuan, representing a year-on-year increase of 14.20% [1] - Net profit attributable to shareholders reached 50.51 million yuan, up 60.66% year-on-year, with a net profit margin improvement [1] - The net profit after deducting non-recurring gains and losses was 46.76 million yuan, reflecting a growth rate of 60.74% [1] Business Operations - The inorganic salt product segment (potassium carbonate/potassium bicarbonate) generated 349 million yuan in revenue, a year-on-year increase of 11.48%, with a gross margin of 20.42% [2] - The veterinary raw material drug segment, particularly the hydrochloride of amprolium, saw revenue of 91.62 million yuan, a significant increase of 66.56% [2] - The fluorine-containing fine chemicals segment experienced a revenue decline of 5.25% to 37.24 million yuan, although gross margin improved to 24.83% [2] Research and Development - The company holds 51 valid invention patents and 21 utility model patents, and has participated in drafting multiple national and industry standards [3] - The company has developed an ion exchange closed-loop system that achieves zero discharge of ammonia nitrogen wastewater, establishing a competitive edge in environmental protection [3] Future Outlook - The company plans to continue focusing on high value-added product development and market expansion domestically, while enhancing its competitive advantages in international markets [3] - Ongoing projects and technological innovations are expected to support revenue growth in the inorganic salt, veterinary raw materials, and fluorine-containing fine chemicals sectors [3]

Group 1 - The company disclosed its main operating data for the first half of 2025, including production, sales, and revenue figures for its key products [1] - The production volume for raw materials was 57,751.21 tons, with sales of 56,707.28 tons, generating a revenue of 365,520.49 million yuan [1] - The production volume for formulations was 25,456.62 tons, with sales of 28,106.62 tons, resulting in a revenue of 117,053.34 million yuan [1] Group 2 - The average selling price for raw materials decreased by 3.04% to 6.45 million yuan per ton, while the average selling price for formulations decreased by 2.89% to 4.16 million yuan per ton [1] - The average procurement price for liquid caustic soda increased by 24.3% to 2,674 yuan per ton, and for hydrogen bromide, it increased by 23.8% to 12,300 yuan per ton [1] - Other raw materials showed varying price changes, with formaldehyde decreasing by 0.4% and acetic acid decreasing by 18.3% [1]

证券代码：600486 证券简称：扬农化工 编号：临 2025-031 江苏扬农化工股份有限公司 2025 年半年度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本公司根据上海证券交易所《上海证券交易所上市公司自律监管指引第 3 号——行业信息披露》、《上市公司行业信息披露指引第十三号——化工》要求， 现将 2025 年半年度主要经营数据披露如下： 一、主要产品的产量、销量及收入实现情况 | 主要产品 | 产量（吨） | 销量（吨） | 营业收入（万元） | | --- | --- | --- | --- | | 原药 | 57,751.21 | 56,707.28 | 365,520.49 | | 制剂（不折百） | 25,456.62 | 28,106.62 | 117,053.34 | 二、主要产品和原材料的价格变动情况 （一）主要产品价格变动情况 | | 2025 年 1-6 月 | 2024 年 1-6 月 | | | --- | --- | --- | --- | | | 平均销售价格 | 平均 ...